Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
نویسندگان
چکیده
Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures. In a phase 1 or 2 dose escalation study, RhD(+) patients (61 subjects) with primary immune thrombocytopenia received a single intravenous dose of rozrolimupab ranging from 75 to 300 μg/kg. The primary outcome was the occurrence of adverse events. The principal secondary outcome was the effect on platelet levels 7 days after the treatment. The most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the patients, respectively, without dose relationship. Rozrolimupab caused an expected transient reduction of hemoglobin concentration in the majority of the patients. At the dose of 300 μg/kg platelet responses, defined as platelet count ≥ 30 × 10(9)/L and an increase in platelet count by > 20 × 10(9)/L from baseline were observed after 72 hours and persisted for at least 7 days in 8 of 13 patients (62%). Platelet responses were observed within 24 hours in 23% of patients and lasted for a median of 14 days. Rozrolimupab was well tolerated and elicited rapid platelet responses in patients with immune thrombocytopenia and may be a useful alternative to plasma-derived products. This trial is registered at www.clinicaltrials.gov as #NCT00718692.
منابع مشابه
Are 25 antibodies better than 1?
In this issue of Blood, Robak et al present data suggesting that rozrolimupab, a firstin-class mixture of 25 recombinant monoclonal IgG1 antibodies against RhD, has efficacy similar to plasma-derived anti-RhD in the treatment of immune thrombocytopenia.1 P lasma-derived anti-RhD, a hyperimmune preparation of IgG that targets the RhD antigen on erythrocytes, is a standard first-line therapy in n...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
Tadeusz Robak,1 Jerzy Windyga,2 Jacek Trelinski,1 Mario von Depka Prondzinski,3 Aristoteles Giagounidis,4 Chantal Doyen,5 Ann Janssens,6 María Teresa Álvarez-Román,7 Isidro Jarque,8 Javier Loscertales,9 Gloria Pérez Rus,10 Andrzej Hellmann,11 Wiesław Wiktor Jêdrzejczak,12 Kazimierz Kuliczkowski,13 Lana M. Golubovic,14 Dusica Celeketic,15 Andrei Cucuianu,16 Emanuil Gheorghita,17 Mihaela Lazaroiu...
متن کاملImmunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)
RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn (HDN) which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody ...
متن کاملRecombinant scFv Antibodies against P30 Surface Protein of Toxoplasma Gondii
Background & Aims: Toxoplasma gondii is an obligate, intracellular parasite, which is widely spread in the world. The parasite is able to infect all warm-blooded hosts including humans and farm animals. The infection in humans often occurs after the ingestion of raw or undercooked meat containing tissue cysts. Several methods have been applied to detect this parasite in contaminated foods. Reco...
متن کاملAntibody Response to Human Extracellular HER2 Subdomain Proteins in Mice
Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses. We have recently reported the immunogenicity of HER2 subdomains following DNA immunization and HER2 protein boosting. In the present study, we evaluated the immunogenicity of different HER2 ex...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 120 18 شماره
صفحات -
تاریخ انتشار 2012